Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Dig Dis Sci. 2018 Aug;63(8):2070–2080. doi: 10.1007/s10620-018-5088-2

Figure 3.

Figure 3

The Future of Biomarkers in the “omics” (R)Evolution. In the era of precision medicine, it is conceivable that patients with Barrett’s esophagus would have testing for germline susceptibility (SNPs) performed on whole-blood DNA, somatic sequencing for mutations or whole genomic doubling performed on Barrett’s tissues specimens acquired by endoscopic biopsy, a family history, and an assessment for environmental risk factors that will all be synthesized into a single, risk prediction model for neoplastic progression.